Altmetric Score

Altmetric Score for Oncotarget Publications Provides Vital Insight, Mikhail (Misha) Blagosklonny says


When it comes to modern medicine, it’s impossible to understate the importance of accuracy. Researchers who are publishing papers on pressing issues must be held to a high standard. The problem is that research outputs can live online and be passionately discussed without ever being thoroughly vetted. Mikhail (Misha) Blagosklonny of Oncotarget knew that a better option had to exist. That’s why Oncotarget, a weekly oncology-focused research journal that was established in 2010, uses easy-to-understand Altmetric scores to shine more light. Authors and readers can now gauge publications alongside Altmetric Article Reports, which provides “real-time feedback that contain a summary of data regarding the online engagement relating to a particular publication.” On its website, Oncotarget has released the list of publications with the score higher than 100 and included these reports, which we will explore below. Mikhail (Misha) Blagosklonny of Oncotarget is proud of this offering and hopes that it helps those with a vested interest in oncology.

“A diagnostic autoantibody signature for primary cutaneous melanoma” carries an Altmetric score of 594. The 2018 study was published by Oncotarget and created by experts from Edith Cowan University, Hollywood Private Hospital, St. John of God Hospital, Dermatology Specialist Group and The University of Western Australia. As the introduction to the study states, “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer,” but the silver lining here is that melanoma “is curable by surgical excision in the majority of cases, if detected at an early stage.”

The paper carries an Altmetric score of 594. Mikhail (Misha) Blagosklonny of Oncotarget knows that readers will want to know what exactly this means. According to the Altmetric website, the number shows “how many people have been exposed to and engaged with a scholarly output.” The melanoma paper, for example, was cited in news articles an impressive 69 times. It was noted in two online blogs, 25 “tweets” on Twitter and on one Facebook page post. Under the headline “New blood test could detect skin cancer early,” FOX23 in Tulsa, Oklahoma took the core content of the study from Australia and shared it with viewers on July 20, 2018.

Another top study from Oncotarget’s list is, “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot,” has a score of 476. This is broken down into 60 news stories from 59 outlets, one online blog post and a half-dozen mentions on Twitter. While the majority of the public may only ever be exposed to a brief overview, those who come to Mikhail (Misha) Blagosklonny and Oncotarget for scientific facts will appreciate these new ratings. Oncotarget is proud to be able to offer web visitors this level of information, as it increases dependability and trust.

http://www.mikhailblagosklonnyoncotarget.com/


When people discuss contemporary medicine, precision plays one of the most significant roles and human lives are literally dependent on it. Hereby, any researches related to medicine are necessary to meet the highest standards. The challenge today is that any results of researches can be posted online and used as a reference without being thoroughly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and decided to create an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality measure. That helps both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website provides a full publications list with corresponding scores above 100 as well as reports discussed above. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it provides the required assistance to anybody, who has interest in oncology.
https://blogs.biomedcentral.com/blog/author/mikhailblagosklonny/
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was released back in 2018 by Oncotarget and written by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are willing to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hereby, the article about melanoma, was used for citations in various news articles 69 times. Moreover, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This research has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a brief overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is glad to have the ability to share with online customers this highly appreciated and top-quality information, that is trustworthy and reliable.
https://sketchfab.com/blagosklonny9

Comments

Post a Comment

Popular posts from this blog

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML ABSTRACT Acute myeloid leukemia (AML) is characterized by an aberrant self-renewal of hematopoietic stem cells (HSC) and a block in differentiation. The major therapeutic challenge is the characterization of the leukemic stem cell as a target for the eradication of the disease. Until now the biology of AML-associated fusion proteins (AAFPs), such as the t(15;17)-PML/RARα, t(8;21)-RUNX1/RUNX1T1 and t(6;9)-DEK/NUP214, all able to induce AML in mice, was investigated in different models and genetic backgrounds, not directly comparable to each other. To avoid the bias of different techniques and models we expressed these three AML-inducing oncogenes in an identical genetic background and compared their influence on the HSC compartment  in vitro  and  in vivo . These AAFPs exerted differential effects on HSCs and PML/RARα, similar to DE...
Read more

Misha Blagosklonny of Oncotarget

Image
Misha Blagosklonny of Oncotarget Welcome to mishablagosklonny.com. Misha Blagosklonny is one of the Editor-in-Chiefs at Oncotarget. The Editorial board at Oncotarget includes the most prominent cancer researchers in the world. In fact, Misha Blagosklonny is proud to say that during a short history of Oncotarget many Editorial Board members have become members of the National Academy of Sciences USA, won Lasker, Nobel and other prestigious awards. The story of Mikhail (Misha) V. Blagosklonny started when he graduated with an MD and PhD from First Pavlov State Medical University of St. Petersburg, Russia. Dr. Misha Blagosklonny of Oncotarget then moved to the United States where he became famous for contributions to  the research of cancer and aging. Everything Dr. Misha Blagosklonny of Oncotarget contributes to is to further understand the cause of cancer and find an efficient treatment. Soon,  Misha Blagosklonny and  Oncotarget will once again be a major part of the Ride ...
Read more

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma ABSTRACT Although new analogues of immunomodulatory drugs (IMiDs) are being developed for MM, the molecular mechanism of these drugs remains unclear. In the current study, we used MM cell lines as a model to investigate the molecular mechanism of thalidomide and to compare its potency with IMiDs such as pomalidomide. We determined that thalidomide did not inhibit cell proliferation of RPMI8226 and U266 MM cells, whereas pomalidomide showed a significant inhibitory effect on these two MM cell lines. Interestingly, we further demonstrated that although thalidomide down-regulated bFGF translation through the inhibition of IRES even at 0.1 µg/ml, pomalidomide did not have a similar affect bFGF levels. A colony formation assay demonstrated that thalidomide and the bFGF knock-down clones caused a significant reduction in the clonogenic ability of MM cells, and treatment with exogenous ...
Read more